CD19 and precursor B-cell acute lymphoblastic leukemia: In addition, we observed similar upregulation of GPR65 expression and activity in adult patients with B-ALL responding to blinatumomab engager without the loss of CD19 expression (Fig. 2G; Supplementary Fig. S1H and S1I).